Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08LVF
|
||||
| Former ID |
DIB004715
|
||||
| Drug Name |
Nitecapone
|
||||
| Synonyms |
OR-462
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Discontinued in Phase 2 | [1] | ||
| Company |
Orion Corp
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H11NO6
|
||||
| Canonical SMILES |
c1([N+](=O)[O-])c(c(cc(C=C(C(=O)C)C(=O)C)c1)O)O
|
||||
| CAS Number |
CAS 116313-94-1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Catechol-O-methyl-transferase | Target Info | Modulator | [2] | |
| BioCyc Pathway | L-dopa degradation | ||||
| Dopamine degradation | |||||
| Noradrenaline and adrenaline degradation | |||||
| KEGG Pathway | Steroid hormone biosynthesis | ||||
| Tyrosine metabolism | |||||
| Metabolic pathways | |||||
| Dopaminergic synapse | |||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Dopamine receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Tyrosine Metabolism | ||||
| WikiPathways | Methylation Pathways | ||||
| Metapathway biotransformation | |||||
| Estrogen metabolism | |||||
| Biogenic Amine Synthesis | |||||
| Dopamine metabolism | |||||
| Phase II conjugation | |||||
| Neurotransmitter Clearance In The Synaptic Cleft | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001267) | ||||
| REF 2 | Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.